Len Rosenberg, head of clinical operations at Beat AML, discusses the outcome of his company's study, which was four years in the making.
In an interview at the 2023 SCOPE conference with ACT Editor-in-Chief, Lisa Henderson, Len Rosenberg, head of clinical operations at Beat AML, updates the public on the trial results (which he was a lead author of) and how the use of precision medicine guidelines played a role.
SCOPE 2024: Todd Everhart of Signant Health Discusses DCTs and Site Burden
February 13th 2024In an interview with ACT editor Andy Studna at SCOPE, Everhart, MD, FACP, clinical vice president, internal medicine, Signant Health discusses decentralized trials and how they may be increasing site burden.
SCOPE 2024: Wendy Morahan of IQVIA Discusses the Use of AI in Clinical Trials
February 13th 2024In an interview with ACT editor Andy Studna at SCOPE, Morahan, senior director, clinical data analytics, IQVIA Technologies discusses how AI can advance trial execution and what stakeholders should be keeping top of mind when choosing technology vendors.